Mia Niklasson
Overview
Explore the profile of Mia Niklasson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
544
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gupta R, Niklasson M, Bergstrom T, Segerman A, Betsholtz C, Westermark B
Sci Rep
. 2024 Jan;
14(1):864.
PMID: 38195678
The migration of neural progenitor cells (NPCs) to their final destination during development follows well-defined pathways, such as along blood vessels. Cells originating from the highly malignant tumor glioblastoma (GBM)...
2.
Larsson I, Dalmo E, Elgendy R, Niklasson M, Doroszko M, Segerman A, et al.
Mol Syst Biol
. 2021 Sep;
17(9):e10105.
PMID: 34528760
Tumor cell heterogeneity is a crucial characteristic of malignant brain tumors and underpins phenomena such as therapy resistance and tumor recurrence. Advances in single-cell analysis have enabled the delineation of...
3.
Dalmo E, Johansson P, Niklasson M, Gustavsson I, Nelander S, Westermark B
Mol Cancer Res
. 2020 Apr;
18(7):981-991.
PMID: 32234828
Glioblastoma multiforme continues to have a dismal prognosis. Even though detailed information on the genetic aberrations in cell signaling and cell-cycle checkpoint control is available, no effective targeted treatment has...
4.
Niklasson M, Bergstrom T, Jarvius M, Sundstrom A, Nyberg F, Haglund C, et al.
J Pathol
. 2019 Jul;
249(3):295-307.
PMID: 31298733
Grade IV astrocytoma/glioblastoma multiforme (GBM) is essentially incurable, partly due to its heterogenous nature, demonstrated even within the glioma-initiating cell (GIC) population. Increased therapy resistance of GICs is coupled to...
5.
Chantzi E, Jarvius M, Niklasson M, Segerman A, Gustafsson M
BMC Bioinformatics
. 2019 Jun;
20(1):304.
PMID: 31164078
Background: Pharmacological treatment of complex diseases using more than two drugs is commonplace in the clinic due to better efficacy, decreased toxicity and reduced risk for developing resistance. However, many...
6.
Chantzi E, Jarvius M, Niklasson M, Segerman A, Gustafsson M
BMC Bioinformatics
. 2018 Nov;
19(1):453.
PMID: 30477419
Background: Large-scale pairwise drug combination analysis has lately gained momentum in drug discovery and development projects, mainly due to the employment of advanced experimental-computational pipelines. This is fortunate as drug...
7.
Kitambi S, Toledo E, Usoskin D, Wee S, Harisankar A, Svensson R, et al.
Cell
. 2017 Jul;
170(2):407.
PMID: 28709005
No abstract available.
8.
Niklasson M, Maddalo G, Sramkova Z, Mutlu E, Wee S, Sekyrova P, et al.
Cancer Res
. 2017 Jan;
77(7):1741-1752.
PMID: 28087597
Glioma-initiating cells (GIC) are considered the underlying cause of recurrences of aggressive glioblastomas, replenishing the tumor population and undermining the efficacy of conventional chemotherapy. Here we report the discovery that...
9.
Segerman A, Niklasson M, Haglund C, Bergstrom T, Jarvius M, Xie Y, et al.
Cell Rep
. 2016 Dec;
17(11):2994-3009.
PMID: 27974212
Intratumoral heterogeneity is a hallmark of glioblastoma multiforme and thought to negatively affect treatment efficacy. Here, we establish libraries of glioma-initiating cell (GIC) clones from patient samples and find extensive...
10.
Darmanis S, Gallant C, Marinescu V, Niklasson M, Segerman A, Flamourakis G, et al.
Cell Rep
. 2016 Jan;
14(2):380-9.
PMID: 26748716
Significant advances have been made in methods to analyze genomes and transcriptomes of single cells, but to fully define cell states, proteins must also be accessed as central actors defining...